Intellia Therapeutics, Inc

NTLANASDAQ · In Vitro & in Vivo Diagnostic Substances

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

140.0M

on 2026-06-30, from 96.3M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

None

No S-3 or F-3 shelf on file in the last 30 months.

$750.0M

Jefferies, agreement of 2026-03-02. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

5.1 quarters

$437.8M on 2026-06-30 ÷ $86.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-04-28	Public offering	16,744,187	not read	not read	424B5 ↗